The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire

Hugh S. Taylor; Eric S. Surrey; Ahmed M. Soliman; Jane Castelli‐Haley; J.P. Rowan; Kristof Chwalisż; James W. Thomas; Brittany Schwefel; Laura Williams; Rinku Jain

doi:10.1016/j.fertnstert.2016.07.271

The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire

Hugh S. Taylor, Eric S. Surrey, Ahmed M. Soliman, Jane Castelli‐Haley, J.P. Rowan, Kristof Chwalisż, James W. Thomas, Brittany Schwefel, Laura Williams, Rinku Jain

In: Fertility and Sterility · 2016 · vol. 106(3) , pp. e93 · doi:10.1016/j.fertnstert.2016.07.271 · W2518189430

article OA: bronze CC0 ⤵ 1 in-corpus citation

🔓 Open OA copy View on OpenAlex View at publisher

⚙ AI-generated summary by claude@2026-07, 2026-07-31 ⓘ

Elagolix significantly improved quality of life for women experiencing endometriosis-associated pain, as measured by the Endometriosis Health Profile Questionnaire in two randomized, placebo-controlled studies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature 2017

Cited by (1)

Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature 2017

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK